BioWa Celebrates One Year Anniversary

Today marks the one year anniversary of the establishment of BioWa, Inc, a revolutionary antibody company based in Princeton, New Jersey. BioWa, Inc, a wholly owned subsidiary of Kyowa Hakko Kogyo Co, Ltd, in Japan (www.kyowa.com), was created to commercially develop Kyowas proprietary "Potelligent" ADCC antibody enhancement technology and to develop Kyowas own antibody business outside of Japan. BioWa will act as a conduit for co-development/co-marketing alliances and licensing deals for Kyowa Hakko Kogyos antibody projects.

(PRWEB) March 7, 2004 --Today marks the one year anniversary of the establishment of BioWa, Inc, a revolutionary antibody company based in Princeton, New Jersey. BioWa, Inc, a wholly owned subsidiary of Kyowa Hakko Kogyo Co, Ltd, in Japan (www.kyowa.com), was created to commercially develop Kyowas proprietary "Potelligent" ADCC antibody enhancement technology and to develop Kyowas own antibody business outside of Japan.

BioWa will act as a conduit for co-development/co-marketing alliances and licensing deals for Kyowa Hakko Kogyos antibody projects.

Dr. Nobuo Hanai, CEO & President of BioWa, commented, The establishment of BioWa is key to the future success of Kyowa Hakko Kogyos long term growth strategy. By positioning the technology in an entrepreneurial environment of a biotech company, the company will realize great success and long-term growth."

Dr. Hanai went on to say, The biopharmaceutical market is rapidly growing, and we are poised to capitalize on the increased demand for antibody-based technologies. Potelligent technology has many years of research behind it and has produced several great clinical candidates thus far. Our technology has proved to be the leading edge in the field of cancer."

Kyowa and BioWa pipeline products featuring the Potelligent antibodies include ecromeximab (KW-2871), an anti-GD chimaeric antibody for malignant malanoma, a GM2 antibody for lung cancer and an anti-GFD2 antibody for neuroblastoma and related malignancies.    

Biowa has already entered into several licensing deals with major industry players.

Dr. Hanai commented, Our first year of operation has been momentous. This is the hallmark of a technology that is certain to revolutionize the treatment of cancer among other life threatening diseases. BioWa has a lot to offer the world of life sciences."    

About BioWa, Inc.Potelligent Technology creates high antigen-dependent cellular cyto-toxicity (ADCC) monoclonal antibodies. ADCC is a function of the immune system that enhances the ability of antibodies to kill tumor cells. The enhancement of ADCC is seen up to 100 fold in vitro. BioWa is currently developing ADCC enhanced monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases and both BioWa and Kyowa have Potelligent antibody products in various clinical stages.

BioWa creates and develops enhanced ADCC antibodies for itself and others, offering a full range of antibody discovery and development capabilities.

For moreinformation about BioWa visit its web site at www.biowa.com.